NCT01923207View on ClinicalTrials.gov

A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

August 12, 2013

Primary Completion Date

January 7, 2014

Study Completion Date

January 7, 2014

Conditions

Hereditary Angioedema (HAE)

Interventions

DRUG

DX-2930

DRUG

Placebo

placebo, subcutaneous administration

Trial Locations (1)

66212

Vince and Associates Clinical Research, Overland Park

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Dyax Corp.

INDUSTRY

lead

Shire

INDUSTRY